Tag Archives: COVID-19

Healthcare M&A Corner – COVID-19 and M&A Transactions: Key Considerations and a Beacon of Light

Normally, my posts describe and analyze specific niche aspects of an M&A deal in order to provide what I hope readers deem as helpful advice.  While the material below initially follows the same roadmap, I also wanted to take this unique opportunity during the COVID-19 pandemic to raise a glass to all of the frontline healthcare, grocery, transit, and other workers risking their lives on a daily basis to save ours, as well as those working in the M&A sphere, including my colleagues and clients, and their advisors and representatives (and dare I say even opposing parties and their teams) who have stepped up their game with respect to collegiality.

As mentioned above, the COVID-19 pandemic has upended the world in countless ways, with healthcare M&A transactions of course having not been spared.  Many promising deals have been placed on hold and the ones powering through will now encounter new hurdles to clear before closing.  Here are some quick issues that M&A parties should consider with the current state in mind.

The Deal Itself

  • Should the parties delay or push forward?
    • If delayed, focus on potential extension of various previously set deadlines:
      • Confidentiality
      • Letter of Intent (binding provisions)
      • Due Diligence Periods, Scope, and Access (also applicable below)
    • If moving forward, consider necessary or resultant changes to (either pre-signing or through a post-signing amendment):
      • Financials
        • Company Results; Valuation
        • Purchase Price
        • Working Capital Adjustments
        • Earn-outs
      • Disclosure Schedules
      • Closing Conditions
        • Third-Party Availability re
          • Regulatory Approvals/Permits
          • Consents to Assignment/Change of Control
        • Material Adverse Effect (Change) Definition
        • Representations and Warranties
        • Indemnification Provisions
        • Force Majeure
        • Operations Between Signing and Closing; Ordinary Course of Business Definition
          • Buyer Consents
          • Seller Carve-Outs for Contingency Measures
        • Termination Provisions

Again, I am happy to report that in my experience, the players behind the deal have largely exhibited a much more cordial and empathetic tone during the COVID-19 pandemic, and I have noticed some very encouraging signs recently.  In addition to a generally softer and more understanding or forgiving tenor, the typical greeting or sign off has resembled some variation of the following: “I hope all is well on your end, and you and your family are staying safe and healthy during these challenging times.”  While it is true that this clause is often stated in response to something similar initiated on my end, I have also observed several opening iterations from all of the M&A players.

It is easy to brush these interactions off, but providing professional services and doing business in a high stakes and fast paced industry is stressful enough (especially at this point in time) so when your “adversaries” become a little less so it makes life that much easier; not to mention treating people with respect is the right thing to do, of course.  My hope is that this type of behavior will last beyond the current state of affairs, but only time will tell.  Have you noticed similar changes in the world of M&A?  If so, do you think such conduct will survive beyond the COVID-19 pandemic?

David Kahn practices in the area of healthcare law, concentrating on Mergers and Acquisitions.

FDA Takes Steps to Enhance Availability of Safe and Effective Face Masks

Over the past week, the U.S. Food & Drug Administration (FDA) has taken a number of steps to enable manufacturers and distributors of face masks to more efficiently make their products available to the marketplace. FDA has accomplished this by establishing criteria that would allow manufacturers to bypass normally required (and often time-consuming) regulatory review.

To read the full text of this Duane Morris Alert, please visit the firm website.

CARES Act Provider Relief Fund $30 Billion Distribution Announced by HHS

Immediate funds are now available for providers to receive a cash influx at a critical time. The challenge will not be receiving the funds, but rather keeping the funds after a future audit of compliance with the terms and conditions.

On April 10, 2020, the United States Department of Health and Human Services (HHS) announced the immediate distribution of an initial $30 billion in relief funding to providers in support of the nationwide COVID-19 response. The distribution is part of the $100 billion provider relief fund included in the Coronavirus Aid, Relief and Economic Security (CARES) Act recently passed by Congress. Importantly, HHS has noted that these are payments, not loans, to healthcare providers, and will not need to be repaid unless the provider does not comply with the terms and conditions.

To read the full text of this Duane Morris Alert, please visit the firm website.

Expansion of Immunity Protections for Covered Countermeasures and Healthcare Volunteers Under CARES Act

As discussed in our March 18 Alert, the Secretary of Health and Human Services has issued a declaration authorizing drugs, devices and biologics used to treat or mitigate COVID-19 as covered countermeasures under the Public Readiness and Emergency Preparedness (PREP) Act. Following Secretary Azar’s declaration of a public health emergency, covered persons may obtain immunity under federal law for all claims arising from manufacturing, distributing or administering covered countermeasures, subject to the conditions laid out at 42 U.S.C. § 247d-6d, the declaration and other applicable regulations.

Subsequent to our previous Alert, President Trump signed into law the Coronavirus Aid, Relief and Economic Security Act (CARES Act), which expanded the covered countermeasure protections offered by the PREP Act.

To read the full text of this Duane Morris Alert, please visit the firm website.

OCR Loosens HIPAA Enforcement Amidst Coronavirus Pandemic

Let’s face it, there has not been much positive news lately surrounding the Coronavirus (“COVID-19”).  However, the Office For Civil Rights (“OCR”), the agency within the Department of Health and Human Services (“HHS”) that enforces the Health Insurance Portability and Accountability Act (“HIPAA”) Privacy and Security Rules, announced several recent measures to allow health care providers avoid certain HIPAA penalties and sanctions amidst the COVID-19 pandemic.

There are several measures OCR/HHS has taken to lessen the regulatory burden of HIPAA for health care providers amidst COVID-19.  Here is the latest breakdown of important pronouncements and guidance set forth by OCR/HHS to help providers deal with COVID-19 and HIPAA compliance:

Continue reading OCR Loosens HIPAA Enforcement Amidst Coronavirus Pandemic